Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure
Laura Michalick, Sarah Weidenfeld, Benjamin Grimmer, Diana Fatykhova, Philip Solymosi, Felix Behrens, Melanie Dohmen, Markus C. Brack, Sabrina Schulz, Elisa Thomasch, Szandor Simmons, Holger Müller-Redetzky, Norbert Suttorp, Florian Kurth, Jens Neudecker, Mario Toennies, Torsten Bauer, Stephan Eggeling, Victor M. Corman, Andreas C. Hocke, Martin Witzenrath, Stefan Hippenstiel, Wolfgang M. Kuebler
Abstract
<b>The plasma of COVID-19 patients induces pulmonary microvascular barrier failure, which increases with disease severity. Here, a screening platform to test for plasma mediators and the therapeutic potential of barrier stabilising compounds is reported.</b>https://bit.ly/3k4C0tB
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)LungSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDiseaseInternal medicinePathologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesHeme Oxygenase-1 and Carbon MonoxideSepsis Diagnosis and Treatment